Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antitumor vaccination: where we stand.

M Bocchia1, V Bronte, M P Colombo

  • 1Department of Hematology, University of Siena, Italy.

Haematologica
|November 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Piezosurgical partial ostectomy of the incisive bone for an ossifying fibroma removal in a 4-year-old Warmblood gelding.

Equine veterinary journal·2026
Same author

New insights into mitochondrial segregation from the Doubly Uniparental Inheritance system in bivalves.

BMC biology·2025
Same author

Headshaking associated with a unique presentation of guttural pouches infection and otitis media in a Quarter Horse stallion: diagnosis, medical treatment and outcome.

Journal of equine veterinary science·2025
Same author

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

European journal of haematology·2024
Same author

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

Frontiers in pharmacology·2023
Same author

Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.

European review for medical and pharmacological sciences·2022

Antitumor vaccination aims to induce immune memory against tumor-associated antigens (TAA). While preclinical models show promise, clinical application requires better patient selection and reliable immune monitoring assays for effective cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Preventive Medicine

Background:

  • Antitumor vaccination leverages tumor-associated antigens (TAA) to induce specific immune memory, aiming to eliminate residual cancer cells and prevent relapse.
  • The cellular basis of this immune memory involves generating persistent T- and B-lymphocyte populations that recognize TAA.
  • Adjuvants and various vaccination strategies, including TAA-based vaccines and antigen-presenting cells, modulate immune memory efficacy.

Purpose of the Study:

  • To review the characterization of TAA.
  • To examine different vaccination strategies in experimental models and preliminary human clinical trials.
  • To discuss challenges and future directions in antitumor vaccination.

Main Methods:

  • Informal consensus development among Working Group members.

Related Experiment Videos

  • Review of articles and abstracts from Science Citation Index and Medline.
  • Inclusion of original research from authors experienced in antitumor immunotherapy.

    • Main Results:

    • Preclinical models demonstrate the potential of active immune induction against TAA for cancer treatment.
    • Several vaccination strategies, including protein/peptide vaccines, viral/bacterial vectors, DNA injection, and dendritic cell-based vaccines, have shown efficacy in experimental models.
    • Phase I/II clinical trials have been conducted in hematologic malignancies and solid tumors.

    Conclusions:

    • Clinical application of antitumor vaccines faces complexities, including patient selection and monitoring.
    • Vaccination is most promising for minimal residual disease or early-stage tumors.
    • Development of reliable assays to monitor patient immune status against TAA is crucial for advancing antitumor vaccine efficacy.